AFF008E:Observational Follow-up Extension Study to Evaluate Long-term Safety and Tolerability of Immunization With AFFITOPE PD01A Applied During AFF008 in Patients With Parkinson's Disease.
Phase of Trial: Phase I
Latest Information Update: 19 Aug 2015
Price : $35 *
At a glance
- Drugs Affitope PD01 (Primary) ; Aluminium oxide
- Indications Parkinson's disease
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 14 Aug 2015 According to the ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
- 26 Feb 2015 Planned primary completion date changed from 1 Mar 2015 to 1 Feb 2015 as reported by ClinicalTrials.gov record.